• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 6, 2015

View Archived Issues

Metabolic/endocrine mash-up Metacrine lines up $36M series A

Arch Venture Partners, Ecor1 Capital, Polaris Partners and Venbio lined up behind Metacrine Inc., a start-up seeking to apply endocrine research to metabolic disease. Read More

Preclinical randomized controlled trial brings stroke of insight

A consortium has reported results from an international randomized controlled trial of the multiple sclerosis drug Tysabri (natalizumab, Biogen Inc.) for the treatment of stroke. Read More

Avax resolves debts and plots course to restart clinical work

Avax Technologies Inc., a Philadelphia-based immunotherapy specialist that ran into financing troubles in 2009, has settled debts it owed the Cancer Treatment Centers of America Inc. (CTCA) and Firebird Management LLC, repaying both parties with equity as it advances plans to re-launch a pivotal clinical study of M-Vax, its candidate immunotherapy for melanoma, and explore resuming a trial of O-Vax, a potential immunotherapeutic vaccine to treat ovarian cancer. Read More

Allergan escapes obviousness with next-gen glaucoma drug

Providing guidance on how to avoid obviousness for next-generation products and what it considers an adequate written description in patent claims, the Federal Circuit upheld several patents relating to a safer, revised formulation of Allergan plc's glaucoma drug Lumigan. Read More

Financings

Critical Outcome Technologies Inc., of London, Ontario, said it completed the final tranche of its non-brokered private placement with the issuance of 2.79 million units at $0.30 each for gross proceeds of approximately C$837,000 (US$634,680). Read More

Stock movers

Read More

Other news to note

Karuna Pharmaceuticals Inc., of Boston, said it received a translation fund award from the Wellcome Trust consisting of an unsecured convertible loan of up to $3.84 million. Read More

In the clinic

Ultragenyx Pharmaceutical Inc., of Novato, Calif., dosed the first patient in a phase II study of recombinant human beta-glucuronidase (rhGUS, UX003) in patients younger than 5 years with mucopolysaccharidosis 7 (MPS 7, or Sly syndrome), potentially including patients with non-immune hydrops fetalis, a severe infantile presentation of the disease. Read More

Earnings

Keryx Biopharmaceuticals Inc., of Boston, reported net sales of phosphate binder Auryxia (ferric citrate) of $1.8 million for the second quarter, based on about 3,700 prescriptions as reported to the company by IMS Health. Read More

Appointments and advancements

Nodality Inc., of South San Francisco, named Kathleen LaPorte CEO. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe